FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011447624> ?p ?o ?g. }

• W3011447624 endingPage "372" @default.
• W3011447624 startingPage "365" @default.
• W3011447624 abstract "To evaluate the safety and effectiveness of fondaparinux in addition to dual antiplatelet therapy (DAPT) in patients with critical limb-threatening ischaemia (CLTI).Fondaparinux (2.5 mg/d) was administered for 1-4 weeks after endovascular procedures together with DAPT (fondaparinux arm). Patients who received standard DAPT were retrospectively matched and generated the control arm. Demographic, angiographic and follow-up data, including (i) clinically relevant bleeding and (ii) target vessel revascularisation or major amputation after 12 months was analysed.Twenty-four patients (78.7 ± 6.9 years, 14 [58%] female, 4 TASC B, 10 TASC C and 10 TASC D lesions, total lesion length = 210 ± 98 mm, mean Rutherford class = 4.7 ± 0.6) received fondaparinux (over a period of 22 ± 9 d, range 7-28 d) and DAPT versus 24 control patients who received standard DAPT (78.3 ± 8.4 years, 14 [58%] female, 4 TASC B, 8 TASC C and 12 TASC D lesions, total lesion length = 204 ± 73 mm, mean Rutherford class = 4.6 ± 0.6). During follow-up, 3(13%) patients in the fondaparinux arm exhibited significant bleeding versus 5 (21%) in the control arm (p = ns). Four (17%) patients of the fondaparinux arm underwent target vessel revascularisation or major amputation versus 6 (25%) in the control group (p = ns).Adding fondaparinux to DAPT does not seem to result in excess of clinically relevant bleeding. Our preliminary data suggest that prospective studies are now warranted in larger patient cohorts.DRKS00015856." @default.
• W3011447624 created "2020-03-23" @default.
• W3011447624 creator A5024301901 @default.
• W3011447624 creator A5046215425 @default.
• W3011447624 creator A5073901682 @default.
• W3011447624 creator A5075701065 @default.
• W3011447624 date "2020-03-13" @default.
• W3011447624 modified "2023-09-25" @default.
• W3011447624 title "Clinical safety of low-dose anticoagulation with fondaparinux in patients undergoing peripheral endovascular treatment due to critical limb-threatening ischaemia – a pilot study" @default.
• W3011447624 cites W200313657 @default.
• W3011447624 cites W2012833937 @default.
• W3011447624 cites W2015845464 @default.
• W3011447624 cites W2016594382 @default.
• W3011447624 cites W2020097503 @default.
• W3011447624 cites W2023122926 @default.
• W3011447624 cites W2024352468 @default.
• W3011447624 cites W2035618791 @default.
• W3011447624 cites W2054253887 @default.
• W3011447624 cites W2058217708 @default.
• W3011447624 cites W2071658386 @default.
• W3011447624 cites W2127985968 @default.
• W3011447624 cites W2139823928 @default.
• W3011447624 cites W2143279870 @default.
• W3011447624 cites W2144985796 @default.
• W3011447624 cites W2163500448 @default.
• W3011447624 cites W2311460389 @default.
• W3011447624 cites W2556414715 @default.
• W3011447624 cites W2556417520 @default.
• W3011447624 cites W2790180402 @default.
• W3011447624 cites W2793477810 @default.
• W3011447624 cites W2793659838 @default.
• W3011447624 cites W2889325201 @default.
• W3011447624 cites W2975859535 @default.
• W3011447624 cites W311320695 @default.
• W3011447624 cites W4244556519 @default.
• W3011447624 doi "https://doi.org/10.1080/00015385.2020.1737782" @default.
• W3011447624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32167029" @default.
• W3011447624 hasPublicationYear "2020" @default.
• W3011447624 type Work @default.
• W3011447624 sameAs 3011447624 @default.
• W3011447624 citedByCount "1" @default.
• W3011447624 countsByYear W30114476242021 @default.
• W3011447624 crossrefType "journal-article" @default.
• W3011447624 hasAuthorship W3011447624A5024301901 @default.
• W3011447624 hasAuthorship W3011447624A5046215425 @default.
• W3011447624 hasAuthorship W3011447624A5073901682 @default.
• W3011447624 hasAuthorship W3011447624A5075701065 @default.
• W3011447624 hasConcept C141071460 @default.
• W3011447624 hasConcept C2776204877 @default.
• W3011447624 hasConcept C2776877702 @default.
• W3011447624 hasConcept C2780868729 @default.
• W3011447624 hasConcept C2991741193 @default.
• W3011447624 hasConcept C71924100 @default.
• W3011447624 hasConceptScore W3011447624C141071460 @default.
• W3011447624 hasConceptScore W3011447624C2776204877 @default.
• W3011447624 hasConceptScore W3011447624C2776877702 @default.
• W3011447624 hasConceptScore W3011447624C2780868729 @default.
• W3011447624 hasConceptScore W3011447624C2991741193 @default.
• W3011447624 hasConceptScore W3011447624C71924100 @default.
• W3011447624 hasFunder F4320310533 @default.
• W3011447624 hasIssue "4" @default.
• W3011447624 hasLocation W30114476241 @default.
• W3011447624 hasLocation W30114476242 @default.
• W3011447624 hasOpenAccess W3011447624 @default.
• W3011447624 hasPrimaryLocation W30114476241 @default.
• W3011447624 hasRelatedWork W1965009178 @default.
• W3011447624 hasRelatedWork W2012720002 @default.
• W3011447624 hasRelatedWork W2016079189 @default.
• W3011447624 hasRelatedWork W2036439935 @default.
• W3011447624 hasRelatedWork W2167051636 @default.
• W3011447624 hasRelatedWork W2301609197 @default.
• W3011447624 hasRelatedWork W2314820193 @default.
• W3011447624 hasRelatedWork W2366666323 @default.
• W3011447624 hasRelatedWork W2397884650 @default.
• W3011447624 hasRelatedWork W4241231482 @default.
• W3011447624 hasVolume "76" @default.
• W3011447624 isParatext "false" @default.
• W3011447624 isRetracted "false" @default.
• W3011447624 magId "3011447624" @default.
• W3011447624 workType "article" @default.